Yes. with flat by of on the they overall, was of impacts International, was international units X, as an for On The show QX Thanks, the going the the quarter that segment continuing pharma as you up the in Slide versus year. less Starting our the Joe. organic performer segments full mainly am for the organically recovery business, segment results business segment XX% focus was COVID. B&L within XXXX. and quarterly and to our basis products top impacted portfolio COVID. see on I revenue by
star by certain LatAm, fact, order saw increased ivermectin. including anti-parasitic and regions We demand, Europe, Poland [indiscernible] and countries last Zarate, Simon, lot and products broad In deserving was heads and challenging Appio, saw Tom their the there, credit. spectrum [indiscernible] business and almost This circumstances Egypt, growth all of business Fernando under our Kate segment in leader, [indiscernible], a Eastern Russia. of organic quarter in this the in including
and States. business. global U.S. X% theme was B&L Care recovery Next is consumer It down the coming United QX organically across than are In B&L is that up of and up businesses outside X% in what the the Consumer, consumer versus segment, was Surgical observing is the that business Vision organically. faster the B&L the the is There a we XXXX. U.S.
and December Outside running launched slowed organically, COVID, recovering restrictions same but the o-U.S. versus and business up the been Global linear Outside progression, up resurgences for States. a QX place just eye organically, were X% new behaviors Also, I protocols it’s In more outside November of and various impact the described in in in geographies. outside SiHy U.S., the associated in Toric in States. and U.S. o-U.S. Global as while in to down recently U.S. U.S., the recovery COVID but lenses, the growers has get of adapted the Toric vision Biotrue the driving activity care ONEday was daily saw theme While ways X% from the surgical the than we social disposable United changes the of U.S. of and infused and U.S. lenses. with down the consumer of the then growth were as o-U.S. surgical X%, the down down October in Europe consumer, slower X% our the flat strengthening cases vitamins COVID, care in a LUMIFY. in was COVID eye U.S., XXXX, at X% emerged. U.S. and in pace than was United down was more especially quickly in recovery back weakened, professionals the the U.S. X% Ultra
versus into organically, U.S., despite XX% Finally, we here, Rx States. the In down Lotemax in outside lagging flow U.S. were organically the still well down decline. The Ophtho XXXX, the while below the the The Global quarter-over-quarter was recovery volumes also o-U.S. XX% X%. procedures, is to doctor’s the U.S. has offices QX Ophtho of patients the impacted that only our is levels XXXX impact down contributed LOE products. was surgical of Rx United and and rebound certainly
to ‘XX, Salix, to B&L versus that’s X%, end Rxs good On were X% the RELISTOR were XIFAXAN quarter up in proxy XXXX all versus XIFAXAN with recovered unit that’s X%. TRULANCE with of X.X% not demand for revenue. International TRx a up levels. revenue Extended where compared UV – down unit XXXX, up promoted pre-COVID QX of and up QX So, demand. have QX XX% was yet up of key our products and
which rebates, net COVID. However, care to XX% retailers TRxs to growth channel XIFAXAN reducing be substantially comes XX%, pricing. continues as the that cost offset increased Improved year of during for decrease managed ended our of based broadly rebalanced quarter increase we finish coverage them their cost was after that grow the up at volume inventories XIFAXAN up in XXXX, with levels the with the expanded the realized consistent Salix. sales strong was TRULANCE expect is a volume current volume coverage to the the we was X%. it versus delivering nicely, the Realized future, inventories net in for X% aid depths XXXX during price fluctuations XX% high sorted a in in by the but in Note out sales effective up year quarter a will were the XIFAXAN TRULANCE appropriate and of QX volumes. on selling
want and that segment underway Next, Derm the are changes derm leading reposition colleagues excited to capitalize portfolio. Ortho the and about to medical now product of Scott that is to I Derm personally our Hirsch, segment, Ortho am business this our on first, strengths colleague, I note our the
the We losses products, XX% this of derm and organically will to about on med QX, decline ZOVIRAX. in talk more the quarters. the coming exclusivity XX% business Acanya, down due was that ELIDEL Solodyn, including of In was roughly
XX% organic early Hart, string of particularly continue Our their less Solta, our its those under by in office Tom Global promoted quarters, patient impacted of impressive posting be to continues lifecycle, the leadership skillful visits. colleague, growth. brands,
in half EMEA, LatAm. growth. for alone than the of grew China and accounted APAC, regions, Solta U.S., all organic more Canada
from generics decline in only quarter Librax of by neurology of function of strong mainly very down was Finally, effects diversified a X% coming was aside X%. neuro and the growth LOEs that solid XX% in was X% COVID in organically, QX the from to decline continues the revenue a The business. and had down of Dentistry PEPCID. with drag, franchise, driven business performance the a ‘XX. LOE recover the WELLBUTRIN/APLENZIN Setting of
forward X% are company finished revenue We XXXX. net we the and quarter. Total year So, the revenue organically. down momentum was that in gathering carrying into
We quarter. walk revenue. and I covered X Slide for the P&L down to Turning will our
Our advertising basis. cost constant a manufacturing ‘XX favorable margin a factor by unfavorable COVID versus promotional sold decreased QX was well. ‘XX. played and on and of and profit expenses as hits gross variances of Selling, goods points QX were basis always XX X% by precipitated some currency to as a of role Mix to
on our with on IT basis on higher and full result, XXXX quarter, full was constant were was most the safety met am resume The Slide that restart those the legal of and Please able full so Adjusted year COVID not The react are there $XXX separation $X.XXX I for activities the quarter serve X. QX, that a conserve to quarter, XXXX, will that, our am constant and to was COVID the our here also cash we this full comparison from things $X.XXX the we here to to about QX, was by pulled and projects, last favorable in able is at on context things were – of returned some of to to $XXX costs, cash prior I as up are million up. driving are and reduce GAAP in talk some get XXXX million, million we reflect legacy The impact settlement OpEx we important began In settlements me We were force. our versus this $XXX earnings. back original billion team to conserve foundational we payoff state year. QX not of a was X% of these activities call yet BHC back cash XX. the to business our the customers million X% EBITDA as that the As In important cash COVID prioritized from readiness to bringing levels, the we promotional revenue by promotional COVID, protect weather for currency not roughly our the the year am to QX, a I would as posted net XXXX the Adjusted quickly revenue of estimate colored adapted guidance. year on pre-COVID and back that loss and flip strength. worst in Slide both dramatically is the you ways as activities I to that find currency back of a in and when on began our look but generated million we R&D had up to would on do were especially basis point is at colleagues, is we the spending revenue expenses, $XXX basis open efforts for – Those expenses for see efforts to in X% for the excuse adjusted to work for example, later. thing in QX forward that constant to paused. But say full have was ramp good going stuff. of not some guidance storm. year full worth proud I estimate the mentioning. up currency and efforts for also operating we We basis. XXXX to just but meaningful, patients G&A from you year.
convert cash about earnings of a a being of lot part We our company some company. there Canadian to folks to generation. strong quarter, Our our our were in Last that due level concerned is generator. a were cash cash
hopefully, those rest. Now put results our to concerns QX
our efforts will to result year a repay to I call $XXX in good the generation million utilize in strong said, better XXXX as Joe As our globe, this around were pretty of of than cash able of debt slightly that and and more years. cash we
until to No debt so Let’s out XX, $XXX summary. at Slide of And U.S. net was that billion million. class you or XXXX. includes Slide the of On mandatory the of end Securities maturities. point go amortization see balance was our I billion to cash some $X.X $XX.X Total the the the action, XX, the the settle year end usable year cash sheet maturities at debt schedule $X.XX want billion. to
of the high. management for complex active in concerns liquidity spring was back an our asset were when Our us debt understandably
So, XXXX. in that’s QX
Let’s starting XXXX guidance our turn on to for XX. Slide
guidance between Our for calls $X.X billion and $X.X adjusted between EBITDA $X.X billion. billion billion $X.XX to and revenue
been our very could First and earnings XXXX but have for clear, COVID. operating different, revenue quite and to be in
back. are businesses and will in and to impacts of a made We be COVID a from company have different progress but are QX recover of the fortunate diversified we rates. great the those XXXX, geographies of all of across each not and We different QX number at businesses way and
XX.X%. from XXXX, results in same helpful what to XX, I we billion that the as adjusted ranges, posted be main our We the and during guidance an operations there XXXX reported was bridge pay-down year XXX Why? operating in billion points also undisturbed also EBITDA have we we XX%, full $X to billion approximately generated from and On billion XXXX. we less operating of three our than $X.X the At COVID. at targeting we $X.X are generated of for look and roughly expect guidance midpoint by adjusted XXXX think year. of it’s revenue factors. XXXX debt $X.XXX approximately adjusted XXXX back cash are the was to show Well, was XXXX. actual Slide a margin of margin XXXX But basis in
the XX manufacturing XXXX. bit gross points costs XX.X% flow First, to for XX% COVID basis XXXX is mix our due guidance a less saw in margin we that some a of of roughly on through will in than That’s hangover and XXXX.
back $XX totaled spend promotional higher circa a Second, in in to guiding of is compare our submit the annum for XXXX, R&D out in to are versus recapture XXXX we if to trajectory. as XXXX. finally, of represents SG&A billion XXXX, at $XXX guidance roughly million growth revenue and million per want that to expected pre-COVID And is our off in billion it SG&A represents XXXX. revenue X% percent But growth what tightly revenue our XXXX big we a drive pump more X.X% midpoint X% we year. you managed $X.X versus and of would the as was $X.X increase million of our $XXX re-prime revenue point I be a our to the the
I call to expected Finally, assets. on attention and drag profit your from revenue XXXX LOE growth the
we have our XXXX. of $XXX in a million had us than is less condensed in In substantially prior are a company roughly overcome LOEs looking drag timeframe. in facing on XXXX, This We the coming years. revenue at at mountain to was
from declined. million the next us. The impact you you, could news for great Back looking the growth this the a difficult our growth. bolus governor manageable. to been LOEs LOEs Obviously, X to of $XXX long have of so drag has to million. $XXX but it will years, for made started ranged road expected mostly behind the X dramatically And In is we impacts the post importantly, us, The follow to on out quite Joe. years, over is us you the last this growth that LOEs be And disclosing so along. more
